Abstracts

QUANTIFYING INDIRECT BENEFITS OF PrEP: MODELING ANALYSIS OF ORAL PrEP IN ZIMBABWE

HIV incidence remains high among adolescent girls and young women (AGYW) in Zimbabwe. Tenofovir-based oral pre-exposure prophylaxis (PrEP) can prevent individual infection, but population level impact and disaggregation of the direct (primary) and indirect (secondary/onward) preventive effects remain unexplored for this population. We assessed potential population-level benefits of oral PrEP use among female sex workers…

A LONG INTERNAL LOOP GOVERNS THE SENSITIVITY OF THE ANTI-HIV PROTEIN SERINC5 TO NEF

We have recently identified the multipass transmembrane proteins SERINC3 and SERINC5 as novel antiviral proteins that restrict HIV-1 infectivity. Nef enhances HIV infectivity by removing SERINCs from the plasma membrane, which prevents their incorporation into progeny HIV-1 virions. However, the determinants that govern the sensitivity of SERINCs to Nef remain unknown. We examined the inhibitory…

INFLAMMATION AND DISEASE RISK AMONG HIV-SEROPOSITIVE INDIVIDUALS

Ongoing systemic inflammation contributes to increased clinical risk among contemporary HIV+ patients despite antiretroviral therapy (ART) treatment with viral suppression. This presentation will review epidemiologic data showing that blood biomarkers, reflecting generalized inflammation, innate immune response (e.g., monocyte activation), adaptive immune response (e.g., T-cell activation), and coagulation activity, predict risk for a broad spectrum of…

THE INTERSECTION OF PrEP AND SEXUALLY TRANSMITTED INFECTIONS

Bacterial sexually transmitted infections (STI) are increasing in the United States at the same time as increases in the awareness and utilization of biomedical advances in HIV treatment (TasP) and prevention (PrEP). In this environment, rates of reported new HIV infections have stabilized, and even declined in some areas. This presentation will examine a confluence…

IMPACT OF PrEP ON HIV INCIDENCE

Among persons at high risk to acquire HIV, oral PrEP has been shown to be effective, with good adherence the infection risk being reduced with 70% or more. Based on these studies PrEP is now recommended for people at substantial risk to acquire HIV. Preventing HIV among high incidence groups will potentially also have a…

FIVE CONTROVERSIES IN PrEP SCALE UP

We know that PrEP is protective and recommended for HIV prevention across populations, with good tolerability and very few safety risks. So what are the remaining controversies that are challenging us as we head towards PrEP scale-up? This talk will tackle five of the debates currently raging: (1) The potential impact of PrEP as a…